We have previously proposed a ‘first-tier’ screening algorithm for SSc-PAH utilising serum N-terminal pro-brain natriuretic peptide (NT-proBNP) levels and pulmonary function tests (PFTs) [14]. This evidence concerns the gene NPPB and pulmonary arterial hypertension.